U.S. Should Take Action To End Drug-Resistant TB

Los Angeles Times: Do we have the will to stop TB?
Caitlin Reed, director of the Inpatient Tuberculosis Unit at Olive View-UCLA Medical Center and assistant professor of infectious diseases at UCLA’s David Geffen School of Medicine

“…Both [extensively drug-resistant (XDR) and multi-drug resistant (MDR)] TB spring from the same roots: inadequate treatment for regular TB, which is often the result of weak public health systems around the world. … It’s a bleak picture, and one that could get worse. In his 2016 budget, President Obama proposed a cut … in funding for global TB programs. However, earlier this year, the White House also announced the development of an ‘action plan’ to stimulate drug-resistant TB research and treatment at home and abroad. The president should request the funding required to implement the plan. … There will be those who say we can’t afford comprehensive action to stop tuberculosis. But … how can we afford not to?” (11/18).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KFF | twitter.com/kff

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.